{"transactions":[{"id":830916,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":267650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.99,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":267650},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":830915,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":267650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":267650,"derivative":{"exercise_price":3.91,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":267650},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":830914,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":830913,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":830912,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":249999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.596,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":249999},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":830911,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:00:23.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":249999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":249999,"derivative":{"exercise_price":3.91,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":249999},"source":{"system":"sec-edgar","filing":"0001193125-26-120192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120192/ownership.xml","form_type":"4"}},{"id":888260,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-23T21:36:44.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":224500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":224500,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":224500},"source":{"system":"sec-edgar","filing":"0001193125-26-064151","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064151/ownership.xml","form_type":"4"}},{"id":888259,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:36:44.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":112250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":368630,"source":{"system":"sec-edgar","filing":"0001193125-26-064151","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064151/ownership.xml","form_type":"4"}},{"id":1125405,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-03T20:46:15.000Z","date":"2025-06-02","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.0665,"value":10665.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.05 to $1.0699 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 145,250 restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date and (ii) a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date."}],"balance_after":256380,"source":{"system":"sec-edgar","filing":"0000950170-25-081041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025081041/ownership.xml","form_type":"4"}},{"id":1238750,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-28T21:22:36.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":290500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."}],"balance_after":290500,"derivative":{"exercise_price":1.13,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":290500},"source":{"system":"sec-edgar","filing":"0000950170-25-030041","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025030041/ownership.xml","form_type":"4"}},{"id":1238749,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-28T21:22:36.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":145250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date."}],"balance_after":246380,"source":{"system":"sec-edgar","filing":"0000950170-25-030041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025030041/ownership.xml","form_type":"4"}},{"id":1361981,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-19T01:51:42.000Z","date":"2024-11-18","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.9994,"value":49970.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019."}],"balance_after":1065766,"source":{"system":"sec-edgar","filing":"0000950170-24-128202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024128202/ownership.xml","form_type":"4"}},{"id":1557655,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:16:24.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":99000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Previously reported on a Form 4 filed on March 18, 2024.  As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":101130,"source":{"system":"sec-edgar","filing":"0001610717-24-000191","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000191/form4.xml","form_type":"4/A","original_submission_date":"2024-03-18"}},{"id":1572702,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-18T23:26:24.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":198000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":198000,"derivative":{"exercise_price":3,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":198000},"source":{"system":"sec-edgar","filing":"0001610717-24-000164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000164/form4.xml","form_type":"4"}},{"id":1572701,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-18T23:26:24.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":99000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":101130,"source":{"system":"sec-edgar","filing":"0001610717-24-000164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000164/form4.xml","form_type":"4"}},{"id":1688338,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T23:05:51.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":2777,"price":20.0945,"value":55802.4265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2023."}],"balance_after":2130,"source":{"system":"sec-edgar","filing":"0001610717-24-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000013/form4.xml","form_type":"4"}},{"id":1893749,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-16T00:01:16.000Z","date":"2023-05-15","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":5.377,"value":53770.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019."}],"balance_after":1015766,"source":{"system":"sec-edgar","filing":"0000899243-23-013012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323013012/doc4.xml","form_type":"4"}},{"id":1993641,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-24T22:36:06.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":267650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023."}],"balance_after":267650,"derivative":{"exercise_price":11.99,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":267650},"source":{"system":"sec-edgar","filing":"0000899243-23-006150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323006150/doc4.xml","form_type":"4"}},{"id":2118308,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-15T01:48:04.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":23,"price":15.04,"value":345.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-035782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035782/doc4.xml","form_type":"4"}},{"id":2118307,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-15T01:48:04.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":4413,"price":15.3248,"value":67628.3424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":4930,"source":{"system":"sec-edgar","filing":"0000899243-22-035782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035782/doc4.xml","form_type":"4"}},{"id":2121334,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-10T01:33:32.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":10111,"price":15.6114,"value":157846.8654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-035472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035472/doc4.xml","form_type":"4"}},{"id":2121333,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-10T01:33:32.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":1255,"price":16.3816,"value":20558.908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":15018,"source":{"system":"sec-edgar","filing":"0000899243-22-035472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035472/doc4.xml","form_type":"4"}},{"id":2121332,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-10T01:33:32.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":5800,"price":15.4117,"value":89387.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":16273,"source":{"system":"sec-edgar","filing":"0000899243-22-035472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035472/doc4.xml","form_type":"4"}},{"id":2123580,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-08T01:19:13.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":2036,"price":16.7171,"value":34036.0156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-035311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035311/doc4.xml","form_type":"4"}},{"id":2123579,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-08T01:19:13.000Z","date":"2022-11-07","kind":"sale","acquired":false,"shares":10167,"price":15.9049,"value":161705.1183,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":6943,"source":{"system":"sec-edgar","filing":"0000899243-22-035311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035311/doc4.xml","form_type":"4"}},{"id":2123578,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-08T01:19:13.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":8828,"price":15.7991,"value":139474.4548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":17110,"source":{"system":"sec-edgar","filing":"0000899243-22-035311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035311/doc4.xml","form_type":"4"}},{"id":2123577,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-08T01:19:13.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":3083,"price":16.0155,"value":49375.7865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":25938,"source":{"system":"sec-edgar","filing":"0000899243-22-035311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035311/doc4.xml","form_type":"4"}},{"id":2123576,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-08T01:19:13.000Z","date":"2022-11-03","kind":"sale","acquired":false,"shares":11082,"price":15.6725,"value":173682.645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":29021,"source":{"system":"sec-edgar","filing":"0000899243-22-035311","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322035311/doc4.xml","form_type":"4"}},{"id":2127335,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-03T00:52:11.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":1544,"price":15.0664,"value":23262.5216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-034840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034840/doc4.xml","form_type":"4"}},{"id":2127334,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-03T00:52:11.000Z","date":"2022-10-31","kind":"sale","acquired":false,"shares":2688,"price":15.3879,"value":41362.6752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":6451,"source":{"system":"sec-edgar","filing":"0000899243-22-034840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034840/doc4.xml","form_type":"4"}},{"id":2130469,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-29T00:27:20.000Z","date":"2022-10-28","kind":"sale","acquired":false,"shares":1683,"price":15.0876,"value":25392.4308,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-034497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034497/doc4.xml","form_type":"4"}},{"id":2130468,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-29T00:27:20.000Z","date":"2022-10-27","kind":"sale","acquired":false,"shares":924,"price":15.3571,"value":14189.9604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":6590,"source":{"system":"sec-edgar","filing":"0000899243-22-034497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034497/doc4.xml","form_type":"4"}},{"id":2131722,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-27T01:19:30.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":1678,"price":15.1025,"value":25341.995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-034294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034294/doc4.xml","form_type":"4"}},{"id":2131721,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-27T01:19:30.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":534,"price":16.2019,"value":8651.8146,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":6585,"source":{"system":"sec-edgar","filing":"0000899243-22-034294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034294/doc4.xml","form_type":"4"}},{"id":2131720,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-27T01:19:30.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":4272,"price":15.6883,"value":67020.4176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":7119,"source":{"system":"sec-edgar","filing":"0000899243-22-034294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034294/doc4.xml","form_type":"4"}},{"id":2131719,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-27T01:19:30.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":2866,"price":16.1701,"value":46343.5066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":11391,"source":{"system":"sec-edgar","filing":"0000899243-22-034294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034294/doc4.xml","form_type":"4"}},{"id":2133058,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-25T01:44:31.000Z","date":"2022-10-21","kind":"sale","acquired":false,"shares":2350,"price":16.6944,"value":39231.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-034092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034092/doc4.xml","form_type":"4"}},{"id":2133057,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-25T01:44:31.000Z","date":"2022-10-21","kind":"sale","acquired":false,"shares":11601,"price":16.2924,"value":189008.1324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":7257,"source":{"system":"sec-edgar","filing":"0000899243-22-034092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034092/doc4.xml","form_type":"4"}},{"id":2133056,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-25T01:44:31.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":31,"price":17.1452,"value":531.5012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":18858,"source":{"system":"sec-edgar","filing":"0000899243-22-034092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034092/doc4.xml","form_type":"4"}},{"id":2133055,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-25T01:44:31.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":7262,"price":16.6814,"value":121140.3268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":18889,"source":{"system":"sec-edgar","filing":"0000899243-22-034092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322034092/doc4.xml","form_type":"4"}},{"id":2270594,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:10:10.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":225000,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-22-018271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018271/doc4.xml","form_type":"4"}},{"id":2313120,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:20.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":4907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4907},"source":{"system":"sec-edgar","filing":"0000899243-22-012989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012989/doc4.xml","form_type":"4"}},{"id":2313119,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":56570,"kind":"person","name":"Easom Eric","position":1,"cik":"0001914503","reported_name":"Easom Eric","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-01T00:15:20.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":4907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."}],"balance_after":4907,"source":{"system":"sec-edgar","filing":"0000899243-22-012989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012989/doc4.xml","form_type":"4"}}]}